Introduction<\/h2>\n
Dystonia is defined as \u2018<\/em>a movement disorder characterised by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures or both\u2019<\/em>.1<\/a> Dystonia in childhood has many causes, the most common being cerebral palsy (CP).2<\/a> Dystonic movements may be painful and can interfere with function and the delivery of daily care. Dystonia may occur in isolation, or as part of a more complex motor disorder. At worst, dystonia may become acutely life-threatening, a condition usually termed \u2018status dystonicus\u2019 (SD).3<\/a> Precisely defining SD remains challenging, though a common definition is of \u2018increasingly frequent and severe episodes of generalised dystonia which had necessitated urgent hospital admission\u2019.<\/em> SD has been reported more often in children and young people (CAYP) than adults, with a trigger identified in around ~60% of cases.5<\/a> While >300 episodes of SD have been reported to date, high-quality prospective studies are entirely lacking.5 6<\/a> The true incidence of SD, or of episodes of worsening dystonia resulting in hospital admission, is unclear and very likely significantly underestimated. Around one in four CAYP experiencing SD fail to return to baseline following the episode, with a reported mortality of ~5%.5<\/a> The risk of developing SD is present for all children with dystonia, though has been most frequently reported in CAYP with dyskinetic CP, pantothenate kinase-associated neurodegeneration and in GNAO1-related dystonia.5<\/a> In the absence of a robust evidence base, this guide will focus on a pragmatic approach to the management of acute dystonia exacerbation.7<\/a> For a more general approach to the diagnosis and management of dystonia in childhood, the reader is directed to the review by Forman and colleagues.8<\/a>\n<\/p>\n<\/div>\n The first challenge when faced in the emergency department (ED) with a CAYP experiencing severe dystonia is being confident that they are not experiencing an epileptic seizure. Prolonged generalised tonic\u2013clonic seizures may be directly harmful to the brain if they continue after 30\u2009min,9<\/a> and in this situation, the aim of treatment is to turn the seizure off<\/em>. In contrast, the aim of acute treatment for severe dystonia is to turn the dystonia down<\/em>. Episodes of SD develop after a period of hours or days of worsening dystonia and lack a clear onset. It usually takes several hours, or even days, to entirely resolve the episode. Figure 1<\/a> outlines some of the ways in which status epilepticus (SE) and SD may be distinguished. CAYP will very often have received a dose of benzodiazepine prior to (or shortly following) arrival in the ED, which can impact on their responsiveness. If there is any question as to whether an episode is a seizure or not, encouraging families to record the movements for review later can be very beneficial. CAYP with dystonia often also present with other hyperkinetic movement disorders\u2014particularly chorea and myoclonus. These movements may also be exacerbated when dystonia worsens, which can further complicate differentiation from SE. Choreiform movements are typically non-rhythmic, random-appearing multiplanar non-purposeful movements. Myoclonic movements are brief, shock-like movements of a muscle group. Myoclonus may be epileptic (cortical myoclonus) or driven by subcortical mechanisms. Differentiation of the two at the bed side is difficult in practice, and an electroencephalogram recording is usually required.<\/p>\n Differentiating episodes of \u2018status dystonicus\u2019 from \u2018status epilepticus\u2019.<\/p>\n<\/div>\n<\/div>\n<\/div>\n A flow chart outlining an approach to managing episodes of acute dystonia exacerbation in CAYP is provided in figure 2<\/a>. This emphasises an \u2018ABCD\u2019 approach. In contrast to the ABCD of Advanced Paediatric Life Support algorithms, these should be considered in parallel rather than sequentially. Grading the severity of dystonia for a CAYP is an important starting point, recognising that symptoms lie on a spectrum of severity, with SD at the most extreme. The Dystonia Severity Action Plan (DSAP) provides a simple 5-point scale for grading dystonia, which is useful for directing the urgency of intervention.10<\/a> CAYP scoring 4 or 5 on this scale are in SD. Most children presenting acutely will be at DSAP grade 3, presenting an opportunity for intervention to prevent any further worsening of symptoms.<\/p>\n An approach to managing acute dystonia. CK, creatine kinase; DBS, deep brain stimulation; HDU, high-dependency unit; ITB, intrathecal baclofen; OPD, outpatient dystonia; PICU, paediatric intensive care unit.<\/p>\n<\/div>\n<\/div>\n<\/div>\n It is difficult to put a fire out if fuel keeps getting thrown onto it. Episodes of worsening dystonia will often (but not always) have a clear trigger, which is important to recognise and treat directly. Figure 3<\/a> provides a summary of common triggers for worsening dystonia, which should be considered for each CAYP. For frank SD, the common triggers differ between CAYP and adults,5<\/a> and include intercurrent infection and changes to medications (either introductions or discontinuation). It is important for all presentations to specifically check if any new medications have been added or discontinued. Each CAYP should also be checked for an implanted device (deep brain stimulator or intrathecal baclofen pump). If one is present\u2014the clinical team managing the device should be contacted urgently.<\/p>\n Triggering factors which may provoke worsening dystonia. CNS, central nervous system; DBS, deep brain stimulation; GORD, gastro-oesophageal reflux disease; ITB, intrathecal baclofen; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection.<\/p>\n<\/div>\n<\/div>\n<\/div>\n As episodes of worsening dystonia take some time to improve, supportive care is required, as are treatments for any complications which may arise. This can include fluid management, pain relief and constipation management. An outline of supportive measures is provided in table 1<\/a>, along with the complications acute dystonia exacerbation may cause to different organ systems. Depending on the severity of the episode, admission to a high dependency (CAYP at DSAP grade 4) or, less commonly, intensive care (CAYP at DSAP grade 5) environment may be required. This may be due to the direct impact of dystonic movements, or the side effects of sedative and other medications (see below) required to control symptoms. One important risk with acute dystonia exacerbation is of rhabdomyolysis resulting in acute kidney injury, which in severe cases may result in the need for renal replacement therapy. While monitoring of plasma electrolyte and creatine kinase levels is necessary, frequency of blood sampling needs to be balanced against the disruptive impact of blood sampling itself on the CAYP. One of the goals of acute treatment is sedation\u2014efforts which painful blood sampling will counteract. Severe dystonia places a significant energy demand on the body, and CAYP may rapidly become catabolic. Early placement of a nasogastric tube should be considered in CAYP without a surgical feeding tube already in place. The safety of a CAYP\u2019s swallow may be compromised by severe dystonia (particularly when this affects the head and neck), further compounded by the adverse effect of sedative medications.<\/p>\n Complications of status dystonicus and support required, organ system by organ system<\/p>\n<\/div>\n<\/div>\n<\/div>\n While triggers are treated, and more dystonia-specific medications are changed (see below), a level of sedation is usually required to reduce distressing symptoms of dystonia. For mild episodes, this may be the very sparing use of a single agent, while for severe episodes of SD, a more complex regimen may be required. Table 2<\/a> provides some details of commonly used tone-reducing medications (TRMs), sedative and non-sedative. A number of different sedative medications have been described in the acute management of severe dystonia, including benzodiazepines, clonidine and chloral hydrate.11<\/a> In all cases, care must be taken with regard to the risk of airway compromise and\/or respiratory depression. For severe episodes of SD, particularly with concurrent rhabdomyolysis, intubation and ventilation may be required. In recent years, concerns have been raised about the use of chloral hydrate outside of the current UK licensing of short-term (not more than 2\u2009weeks) treatment of insomnia in children with neurodevelopmental disorders. Consensus guidance has been produced to provide a framework for the use of this medication for CAYP with severe movement disorders.12<\/a>\n<\/p>\n Tone-reducing medications (TRMs) used in the management of dystonia<\/p>\n<\/div>\n<\/div>\n<\/div>\n Sedative strategies provide a period of symptom control while changes are made to background TRMs. A large number of TRMs have been described in the management of worsening dystonia and SD, with varying efficacy reported.3 11<\/a> Table 2<\/a> provides details of some of the more commonly used medications, along with common side effects. Factors to consider when selecting a TRM are outlined in Box 1<\/a>. For episodes of severe SD, the potential benefits of neurosurgical interventions such as deep brain stimulation (DBS) have been increasingly reported.5 13<\/a> It remains unclear which CAYP are optimal candidates for DBS (or in some cases intrathecal baclofen) and at what time point during an episode of SD. All children admitted to an intensive care setting due to dystonia should be discussed early with a service which is experienced in the delivery of DBS to CAYP.<\/p>\n TRMs the CAYP is already receiving.<\/p>\n<\/li>\n Background comorbidities which might be particularly worsened by the specific side effects of a given medication (eg, for a severely constipated child, an anticholinergic medication like trihexyphenidyl would be used with caution).<\/p>\n<\/li>\n The overall profile of the motor disorder for a CAYP (eg, co-incident spasticity would suggest potential benefits with the addition of baclofen).<\/p>\n<\/li>\n The speed at which symptom control is required (eg, a slow titration of trihexyphenidyl is required to limit the impact of anti-cholinergic side effects which may in term limit its use in a very acute situation).<\/p>\n<\/li>\n Whether a TRM could additionally help with treating a trigger (eg, gabapentin may have an additional analgesic effect in the CAYP with worsening dystonia due to pain from a subluxation of the hip).<\/p>\n<\/li>\n<\/ul>\n CAYP, children and young people.<\/p>\n<\/div>\n The evidence base for TRMs used in the management of dystonia is extremely limited,14<\/a> and side effects limiting use are commonly experienced by CAYP.15<\/a> During severe exacerbation of dystonia, it may be necessary to introduce or increase several TRMs, and it is important following an episode that there is close follow-up to try and rationalise ongoing medication use.<\/p>\n<\/div>\n CAYP experiencing an episode of worsening dystonia or SD will require close follow-up, for the reasons outlined in Box 2<\/a>. Unfortunately, CAYP who have experienced an episode of worsening dystonia are at risk of experiencing further such episodes in the future. Given this risk, and the lack of standardised guidelines for the management of worsening dystonia, all children who have experienced an episode of worsening dystonia necessitating hospital admission should be provided with a personalised plan for dystonia management, providing (a) guidance on medication changes to be made if dystonia acutely worsens, (b) advice on how to manage medications if CAYP are made nil by mouth and (c) the contact details for the team responsible for managing a CAYP\u2019s dystonia. The British Paediatric Neurology Association provides blank dystonia passports which can be adapted to an individual CAYP, along with guidance as to how these forms should be completed.16<\/a> These plans should be documented in patient notes, with a copy provided to parents\/carers to carry.<\/p>\n
\n4<\/a>\n<\/p>\nGetting the right status: dystonia or epilepsy?<\/h2>\n
![\"Figure](\"https:\/\/ep.bmj.com\/content\/edpract\/110\/1\/8\/F1.medium.gif\")
<\/span><\/div>\n<\/div>\n<\/div>\nManaging episodes of acute dystonia exacerbation<\/h2>\n
![\"Figure](\"https:\/\/ep.bmj.com\/content\/edpract\/110\/1\/8\/F2.medium.gif\")
<\/span><\/div>\n<\/div>\n<\/div>\nWhy has dystonia worsened?\u2014A<\/span>ddressing the precipitant<\/h2>\n
![\"Figure](\"https:\/\/ep.bmj.com\/content\/edpract\/110\/1\/8\/F3.medium.gif\")
<\/span><\/div>\n<\/div>\n<\/div>\nGeneral management\u2014B<\/span>eginning supportive care<\/h2>\n
Temporising measures\u2014C<\/span>alibrating sedation<\/h2>\n
Improving abnormal tone\u2014D<\/span>ystonia-specific medications<\/h2>\n
Factors to consider when selecting tone-reducing medications (TRMs)<\/h3>\n
\n
After the episode: follow-up and after care<\/h2>\n